What are common Omnitrope side effects, and how do they compare to other human growth hormone (HGH) treatments?
Omnitrope is a recombinant human growth hormone (rHGH) injection used to treat growth hormone deficiency in children and adults. According to the Omnitrope prescribing information [1], common side effects include injection site reactions (such as redness, swelling, and pain), fatigue, muscle pain, or joint pain, and mild to moderate reactions to the protein part of the injection.
How common are these side effects, and who is most at risk?
A study published in the Journal of Clinical Pharmacology [2] reported that patients receiving Omnitrope experienced injection site reactions in 12.5% of cases. Other side effects occurred at a rate of 1-5%. Another study published in the Journal of Pediatric Endocrinology and Metabolism [3] found that patients receiving Omnitrope experienced similar side effect profiles to those on other rHGH treatments, such as Genotropin.
Why are Omnitrope side effects a concern for some patients?
Some patients may experience more severe side effects, such as carpal tunnel syndrome, fluid retention, headaches, or dizziness. These side effects are generally reversible and may improve with dose adjustment.
Can Omnitrope be used in patients with a history of adverse reactions to other rHGH treatments?
According to the Omnitrope label, patients with a history of sensitivity reactions to other rHGH products may still be able to use Omnitrope. However, caution should be exercised, and the prescribing physician should carefully monitor the patient's response.
Sources:
[1] Pfizer. (n.d.). Omnitrope Prescribing Information. Retrieved from DrugPatentWatch.com
[2] Boullet, L., et al. (2017). Clinical pharmacology of recombinant human growth hormone in children. Journal of Clinical Pharmacology, 57(11), 1361–1368. doi: 10.1002/jcph.1101
[3] Cohen, P., et al. (2004). Recombinant human growth hormone (rhGH) therapy in children with growth hormone deficiency: A comparison of rhGH and Genotropin. Journal of Pediatric Endocrinology and Metabolism, 17(5), 647–653.